Mangiferin attenuates renal fibrosis through down-regulation of osteopontin in diabetic rats

Phytotherapy Research

Volumn 29, Issue 2, 2015, Pages 295-302

  Zhu, Xia ^a   Cheng, Ya Qin ^a   Du, Lei ^a   Li, Yu ^a   Zhang, Fan ^a   Guo, Hao ^a   Liu, Yao Wu ^a   Yin, Xiao Xing ^a  

^a XUZHOU MEDICAL UNIVERSITY   (China)

Author keywords

Diabetic nephropathy; Glomerulus fibrosis; Inflammation; Mangiferin; Osteopontin

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; COLLAGEN TYPE 4; CYCLOOXYGENASE 2; INTERLEUKIN 1BETA; MANGIFERIN; MESSENGER RNA; OSTEOPONTIN; STREPTOZOCIN; TRANSCRIPTION FACTOR RELA; ACTIN; GLUCOSE BLOOD LEVEL; PTGS2 PROTEIN, RAT; RELA PROTEIN, RAT; SMOOTH MUSCLE ACTIN, RAT; SPP1 PROTEIN, RAT; XANTHONE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD LEVEL; BODY WEIGHT; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DIET RESTRICTION; DOWN REGULATION; DRUG EFFECT; DRUG MECHANISM; GLOMERULUS; KIDNEY CORTEX; KIDNEY FIBROSIS; MALE; NEPHRITIS; NONHUMAN; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; STREPTOZOTOCIN-INDUCED DIABETES MELLITUS; ANALYSIS; ANIMAL; DRUG EFFECTS; EXPERIMENTAL DIABETES MELLITUS; FIBROSIS; GLUCOSE BLOOD LEVEL; INFLAMMATION; KIDNEY DISEASE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; SPRAGUE DAWLEY RAT;

RATTUS;

ACTINS; ANIMALS; BLOOD GLUCOSE; BODY WEIGHT; COLLAGEN TYPE IV; CYCLOOXYGENASE 2; DIABETES MELLITUS, EXPERIMENTAL; DOWN-REGULATION; FIBROSIS; INFLAMMATION; INTERLEUKIN-1BETA; KIDNEY DISEASES; KIDNEY GLOMERULUS; MALE; OSTEOPONTIN; RATS; RATS, SPRAGUE-DAWLEY; RNA, MESSENGER; STREPTOZOCIN; TRANSCRIPTION FACTOR RELA; XANTHONES;

EID: 84922795099     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5254     Document Type: Article

References (49)

1. Ashkar S, Weber GF, Panoutsakopoulou V et al. 2000. Eta-1 (osteopontin): an early component of type-1 (cell-mediated) immunity. Science 287: 860-864.
2. Bhatia HS, Candelario-Jalil E, de Oliveira AC, Olajide OA, Martinez-Sanchez G, Fiebich BL. 2008. Mangiferin inhibits cyclooxygenase-2 expression and prostaglandin E2 production in activated rat microglial cells. Arch Biochem Biophys 477: 253-258.
3. Bidder M, Shao JS, Charlton-Kachigian N, Loewy AP, Semenkovich CF, Towler DA. 2002. Osteopontin transcription in aortic vascular smooth muscle cells is controlled by glucose-regulated upstream stimulatory factor and activator protein-1 activities. J Biol Chem 277: 44485-44496.
4. Brownlee M. 2001. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820.
5. Brownlee M. 2005. The pathobiology of diabetic complications: a unifying mechanism. Diabetes 54: 1615-1625.
6. Chow FY, Nikolic-Paterson DJ, Atkins RC, Tesch GH. 2004. Macrophages in streptozotocin-induced diabetic nephropathy: potential role in renal fibrosis. Nephrol Dial Transplant 19: 2987-2996.
7. Denhardt DT, Giachelli CM, Rittling SR. 2001. Role of osteopontin in cellular signaling and toxicant injury. Annu Rev Pharmacol Toxicol 41: 723-749.
8. Elmarakby AA, Sullivan JC. 2012. Relationship between oxidative stress and inflammatory cytokines in diabetic nephropathy. Cardiovasc Ther 30: 49-59.
9. Fischer JW, Tschope C, Reinecke A, Giachelli CM, Unger T. 1998. Upregulation of osteopontin expression in renal cortex of streptozotocin-induced diabetic rats is mediated by bradykinin. Diabetes 47: 1512-1518.
10. Ghosh M, Das J, Sil PC. 2012. D(+) galactosamine induced oxidative and nitrosative stress-mediated renal damage in rats via NF-kappaB and inducible nitric oxide synthase (iNOS) pathways is ameliorated by a polyphenol xanthone, mangiferin. Free Radic Res 46: 116-132.
11. Gong X, Zhang L, Jiang R,Ye M,YinX,Wan J. 2013. Anti-inflammatory effects of mangiferin on sepsis-induced lung injury in mice via up-regulation of heme oxygenase-1. J Nutr Biochem 24: 1173-1181.
12. Hsieh TJ, Chen R, Zhang SL et al. 2006. Upregulation of osteopontin gene expression in diabetic rat proximal tubular cells revealed by microarray profiling. Kidney Int 69: 1005-1015.
13. Junaid A, Amara FM. 2004. Osteopontin: correlation with interstitial fibrosis in human diabetic kidney and PI3-kinase-mediated enhancement of expression by glucose in human proximal tubular epithelial cells. Histopathology 44: 136-146.
14. Kelly DJ, Wilkinson-Berka JL, Ricardo SD, Cox AJ, Gilbert RE. 2002. Progression of tubulointerstitial injury by osteopontininduced macrophage recruitment in advanced diabetic nephropathy of transgenic (mRen-2)27 rats. Nephrol Dial Transplant 17: 985-991.
15. Kramer AB, Ricardo SD, Kelly DJ, Waanders F, van Goor H, Navis G. 2005. Modulation of osteopontin in proteinuria-induced renal interstitial fibrosis. J Pathol 207: 483-492.
16. Li X, Cui X, Sun X, Li X, Zhu Q, Li W. 2010. Mangiferin prevents diabetic nephropathy progression in streptozotocin-induced diabetic rats. Phytother Res 24: 893-899.
17. Liu YW, Zhu X, Yang QQ et al. 2013a. Suppression of methylglyoxal hyperactivity by mangiferin can prevent diabetes-associated cognitive decline in rats. Psychopharmacology (Berl) 228: 585-594.
18. Liu YW, Zhu X, Zhang L et al. 2013b. Up-regulation of glyoxalase 1 by mangiferin prevents diabetic nephropathy progression in streptozotocin-induced diabetic rats. Eur J Pharmacol 721: 355-364.
19. Lorenzen J, Shah R, Biser A et al. 2008. The role of osteopontin in the development of albuminuria. J Am Soc Nephrol 19: 884-890.
20. Madrigal JL, Moro MA, Lizasoain I et al . 2003. Induction of cyclooxygenase-2 accounts for restraint stress-induced oxidative status in rat brain. Neuropsychopharmacology 28: 1579-1588.
21. Makino H, Miyamoto Y, Sawai K et al. 2006. Altered gene expression related to glomerulogenesis and podocyte structure in early diabetic nephropathy of db/db mice and its restoration by pioglitazone. Diabetes 55: 2747-2756.
22. Marquez L, Garcia-Bueno B, Madrigal JL, Leza JC. 2012. Mangiferin decreases inflammation and oxidative damage in rat brain after stress. Eur J Nutr 51: 729-739.
23. Martinez Sanchez G, Candelario-Jalil E, Giuliani A et al. 2001. Mangifera indica L. extract (QF808) reduces ischaemiainduced neuronal loss and oxidative damage in the gerbil brain. Free Radic Res 35: 465-473.
24. Miura T, Ichiki H, Iwamoto N et al . 2001. Antidiabetic activity of the rhizoma of Anemarrhena asphodeloides and active components, mangiferin and its glucoside. Biol Pharm Bull 24: 1009-1011.
25. Mogensen CE. 1976. Renal function changes in diabetes. Diabetes 25: 872-879.
26. Muruganandan S, Gupta S, Kataria M, Lal J, Gupta PK. 2002. Mangiferin protects the streptozotocin-induced oxidative damage to cardiac and renal tissues in rats. Toxicology 176: 165-173.
27. Muruganandan S, Srinivasan K, Gupta S, Gupta PK, Lal J. 2005. Effect of mangiferin on hyperglycemia and atherogenicity in streptozotocin diabetic rats. J Ethnopharmacol 97: 497-501.
28. Nelson CL, Karschimkus CS, Dragicevic G et al. 2005. Systemic and vascular inflammation is elevated in early IgAand type 1 diabetic nephropathies and relates to vascular disease risk factors and renal function. Nephrol Dial Transplant 20: 2420-2426.
29. Nguyen D, Ping F, Mu W, Hill P, Atkins RC, Chadban SJ. 2006. Macrophage accumulation in human progressive diabetic nephropathy. Nephrology (Carlton) 11: 226-231.
30. Nicholas SB, Liu J, Kim J et al. 2010. Critical role for osteopontin in diabetic nephropathy. Kidney Int 77: 588-600.
31. O'Regan A, Berman JS. 2000. Osteopontin: a key cytokine in cellmediated and granulomatous inflammation. Int J Exp Pathol 81: 373-390.
32. Pan Y,Wang Y, Cai L et al. 2012. Inhibition of high glucose-induced inflammatory response and macrophage infiltration by a novel curcumin derivative prevents renal injury in diabetic rats. Br J Pharmacol 166: 1169-1182.
33. Prabhu S, JainuM, Sabitha KE, Devi CS. 2006. Role ofmangiferin on biochemical alterations and antioxidant status in isoproterenolinduced myocardial infarction in rats. J Ethnopharmacol 107: 126-133.
34. Rivera DG, Hernandez I, Merino N et al. 2011. Mangifera indica L. extract (Vimang) and mangiferin reduce the airway inflammation and Th2 cytokines in murine model of allergic asthma. J Pharm Pharmacol 63: 1336-1345.
35. Rivero A, Mora C, Muros M, Garcia J, Herrera H, Navarro-Gonzalez JF. 2009. Pathogenic perspectives for the role of inflammation in diabetic nephropathy. Clin Sci (Lond) 116: 479-492.
36. Samant RS, Clark DW, Fillmore RA et al. 2007. Breast cancer metastasis suppressor 1 (BRMS1) inhibits osteopontin transcription by abrogating NF-kappaB activation. Mol Cancer 6: 6-14.
37. Sanchez AP, Sharma K. 2009. Transcription factors in the pathogenesis of diabetic nephropathy. Expert Rev Mol Med 11: e13.
38. Saraheimo M, Teppo AM, Forsblom C, Fagerudd J, Groop PH. 2003. Diabetic nephropathy is associated with low-grade inflammation in Type 1 diabetic patients. Diabetologia 46: 1402-1407.
39. Schmid H, Boucherot A, Yasuda Y et al. 2006. Modular activation of nuclear factor-kappaB transcriptional programs in human diabetic nephropathy. Diabetes 55: 2993-3003.
40. Soetikno V, Sari FR, Veeraveedu PT et al. 2011. Curcumin ameliorates macrophage infiltration by inhibiting NF-kappaB activation and proinflammatory cytokines in streptozotocin induced-diabetic nephropathy. Nutr Metab (Lond) 8: 35-45.
41. Susztak K, Bottinger E, Novetsky A et al. 2004. Molecular profiling of diabetic mouse kidney reveals novel genes linked to glomerular disease. Diabetes 53: 784-794.
42. Tuttle KR. 2005. Linking metabolism and immunology: diabetic nephropathy is an inflammatory disease. J Am Soc Nephrol 16: 1537-1538.
43. Wang LH, Liu JS, Ning WB et al. 2011. Fluorofenidone attenuates diabetic nephropathy and kidney fibrosis in db/db mice. Pharmacology 88 : 88-99.
44. Wojcikowski K, Wohlmuth H, Johnson DW, Gobe G. 2010. Effect of Astragalus membranaceus and Angelica sinensis combined with Enalapril in rats with obstructive uropathy. Phytother Res 24: 875-884.
45. Xie Y, Sakatsume M, Nishi S, Narita I, Arakawa M, Gejyo F. 2001. Expression, roles, receptors, and regulation of osteopontin in the kidney. Kidney Int 60: 1645-1657.
46. Xie XS, Liu HC, Wang FP et al. 2010. Ginsenoside Rg1 modulation on thrombospondin-1 and vascular endothelial growth factor expression in early renal fibrogenesis in unilateral obstruction. Phytother Res 24: 1581-1587.
47. Yamaguchi H, Igarashi M, Hirata A et al. 2004. Progression of diabetic nephropathy enhances the plasma osteopontin level in type 2 diabetic patients. Endocr J 51: 499-504.
48. Yan X, Sano M, Lu L et al. 2010. Plasma concentrations of osteopontin, but not thrombin-cleaved osteopontin, are associated with the presence and severity of nephropathy and coronary artery disease in patients with type 2 diabetes mellitus. Cardiovasc Diabetol 9: 70-77.
49. Yuan XP, Liu LS, Fu Q, Wang CX. 2012. Effects of ligustrazine on ureteral obstruction-induced renal tubulointerstitial fibrosis. Phytother Res 26: 697-703.